March 2016, Vol. 5, No. 2
The Wide Range of Topics Under the Personalized Care UmbrellaLetter to Our Readers
One important lesson we have learned from our work in personalizing care for oncology patients is that there are many more considerations in implementing care aside from the obvious premises of targeted therapies, companion diagnostics, and next-generation sequencing. There is an ever-broadening array of considerations that goes into providing optimal care to an individual patient at the appropriate time. Our diverse editorial lineup in this issue provides evidence of this fact.
We present a discussion with Suso J. Platero, PhD, in our Interview with the Innovators series. Dr Platero provides his perspective as a researcher at Janssen Pharmaceuticals on the front lines of scientific discoveries that can ultimately impact oncology care. This all-important work represents the genesis of our ability to continue to improve care, and we are pleased to have had the opportunity to interview Dr Platero.
It is imperative to recognize the regulatory component of personalized care. Michael Shea, Jeff Allen, PhD, and Ellen Sigal, PhD, from Friends of Cancer Research highlight the history of legislation that created the regulatory framework overseeing products in personalized medicine.
An area that has recently been elevated in importance is that of genetic counseling. With improvements in our ability to screen more people for genetic mutations, this field is on the forefront of prevention and treatment. In this issue, you will find Ms Radford’s paper on the evolving phenotype of Li-Fraumeni syndrome.
We continue our coverage of immunotherapies as an integral part of precision medicine’s approach to treating cancer patients. This month we explore immunotherapies in pancreatic cancer in the hope of shedding light on the coming therapeutics in this historically difficult-to-treat disease.
As always, we welcome your letters to the editor with comments on the current articles, your submissions to the publication, or questions for our board. We look forward to hearing from you at firstname.lastname@example.org.
Al B. Benson III, MD, FACP, FASCO
Co-editor in Chief
Personalized Medicine in Oncology
Tamoxifen and anastrozole are similarly effective in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ (DCIS). The choice depends on patient preferences, side effect profiles, age, and other patient factors, according to separate studies presented at the 2015 San Antonio Breast Cancer Symposium.In the large, placebo-controlled [ Read More ]
According to the American Cancer Society, an estimated 48,960 new cases of pancreatic cancer and 40,560 deaths due to the disease were expected to occur in the United States in 2015.1 Survival statistics for pancreatic cancer are bleak: for all stages combined, the 1- and 5-year relative survival rates are [ Read More ]